Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Pfizer Q3 2026 Results: Net Income $3.24B, Down 8.4% YoY

For the three months ended September 27, 2026, Pfizer reported total revenues of $16.58 billion, a slight decrease from $16.65 billion in the prior year period. Net income attributable to common shareholders for the quarter was $3.24 billion ($0.56 per diluted share), down from $3.54 billion ($0.62 per diluted share) in the same period of 2025.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue16,583.016,654.0
Profit before tax3,385.03,334.0
Net income3,242.03,541.0
EPS (diluted, $ a share)$0.56$0.62

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year-8.4%
Revenue, year on year-0.4%
Source

10-Q filed with the SEC, NYSE: PFE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Pfizer Inc: key numbers

Share price
$28.86Close, Nov 16
Market cap
$164B
Shares outstanding
5.7BLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Pfizer Inc

All →
4:20 PM ET 8-K
Leadership Change

Pfizer Leadership Change

Pfizer Inc. has appointed Cecile Guegan as Chief Financial Officer and Executive Vice President, effective November 1, 2026. Ms. Guegan, who had been serving as Interim CFO since August 2026, will receive an annual base salary of $1.3 million and a target cash incentive opportunity of 100% of her base salary.

8:08 AM ET 8-K
Financial Results

Pfizer Financial Results

Pfizer reported Q3 2026 revenues of $16.6 billion, with 32% operational growth from launched and acquired products. The company raised its full-year 2026 revenue guidance to $62.0-$64.0 billion and appointed Cecile Guegan as its new Chief Financial Officer.

Term
Q3 2026

“Pfizer had another strong quarter with commercial momentum and disciplined execution while advancing our strategy for creating long-term shareholder value. Our obesity program continued to advance and recent milestones in oncology, immunology and vaccines further demonstrate the potential of our pipeline. With a robust slate of expected catalysts ahead, I believe we're well positioned to deliver meaningful new medicines for patients and lasting value in the years ahead.”

Dr. Albert Bourla, Chairman and CEO of Pfizer

“Our third-quarter results reflect strong commercial performance globally and continued operational discipline. This quarter, our non-COVID products delivered strong 7% operational revenue growth, and I’m particularly pleased with the 32% year-over-year operational revenue growth from our launched and acquired products. Today, we are raising our full-year 2026 Revenue and Adjusted diluted EPS guidance, reflecting our strong year-to-date performance and confidence in our business.”

Cecile Guegan, CFO and EVP of Pfizer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.